Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
BM (Hons) FRCP DM
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling.
Yeo T. et al, (2019), Neurol Neuroimmunol Neuroinflamm, 6
β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Vanhaesebrouck AE. et al, (2019), Brain
Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA. et al, (2019), Neurology
Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
Mariano R. et al, (2019), JAMA Netw Open, 2
A large international aquaporin-4 antibody data set: combines individual factors to predict prognosis, identifies the risk of post-onset attack disability and calculates the power for future clinical trials
Nakashima I. et al, (2019), MULTIPLE SCLEROSIS JOURNAL, 25, 90 - 90